Pre-made Bimagrumab benchmark antibody ( Whole mAb, anti-ACVR2B therapeutic antibody, Anti-ACTRIIB/ActR-IIB/HTX4 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Bimagrumab biosimilar, Whole mAb, Anti-ACVR2B Antibody: Anti-ACTRIIB/ActR-IIB/HTX4 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Bimagrumab (BYM338) is a human monoclonal antibody developed by Novartis to treat pathological muscle loss and weakness. On August 20, 2013, it was announced that bimagrumab had received a breakthrough therapy designation for sporadic inclusion body myositis (sIBM) by the US Food and Drug Administration.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	List Price(In USD)	Discount off	Discount Price
GMP-Bios-ab-069-1mg	1mg	3090	Inquiry	Inquiry

Size： 1mg | 10mg | 100mg

Description

Products Name (INN Index)	Pre-Made Bimagrumab biosimilar, Whole mAb, Anti-ACVR2B Antibody: Anti-ACTRIIB/ActR-IIB/HTX4 therapeutic antibody
INN Name	Bimagrumab
Target	ACVR2B
Format	Whole mAb
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Lambda
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Active
100% SI Structure	5nhr:HL:AB
99% SI Structure	5nhw:HL/5nh3:HL:IM/5ngv:HL
95-98% SI Structure	None
Year Proposed	2012
Year Recommended	2013
Companies	MorphoSys;Novartis
Conditions Approved	na
Conditions Active	Cachexia;Muscular atrophy;Type 2 diabetes mellitus
Conditions Discontinued	Inclusion body myositis
Development Tech	MorphoSys HuCAL Phage Display